期刊文献+

Erbin基因沉默对乳腺癌细胞生物学行为的影响 被引量:1

Effect of RNA interference targeting Erbin gene on the biological behavior of breast carcinoma cells
原文传递
导出
摘要 目的:观察Erbin基因表达沉默后对乳腺癌细胞形态及侵袭迁移生物学行为的影响。方法:通过慢病毒shRNA转染技术建立低表达Erbin的乳腺癌细胞模型。蛋白质印迹法检测基因沉默前后Erbin蛋白表达的效果;倒置显微镜观察基因沉默前细胞形态改变;Matrigel-Transwell小室法检测细胞侵袭能力改变;Transwell小室法检测细胞迁移能力改变。蛋白质印迹法检测转移相关基因基质金属蛋白酶-2(matrix metallopro teinase-2,MMP-2)和基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)表达改变。结果:成功建立了Erbin基因沉默乳腺癌细胞模型。蛋白质印迹法显示,稳定表达Erbin-shRNA细胞的Erbin蛋白表达明显被抑制,Erbin基因沉默后乳腺癌细胞变长、变梭,细胞间隙明显增宽,侵袭能力为56.3±7.6,明显高于空载体转染组的29.3±2.1,t=-5.908,P=0.004;迁移能力为83.6±7.2,较空载体转染组的52.6±8.3显著增强,t=-4.868,P=0.008。Erbin-shRNA转染后转移相关基因MMP-2表达为0.74±0.021,较空载体组的0.25±0.039明显上调,t=-19.23,P<0.001;MMP-9的表达为0.78±0.037,较空载体组的0.32±0.078也显著上调,t=-10.02,P=0.001。结论:Erbin基因的表达沉默对乳腺癌细胞的部分恶性生物学行为的发生有一定促进作用,可促进细胞变长、变梭,促进细胞侵袭迁移能力增强。 OBJECTIVE:To study the effect of RNA interference targeting Erbin gene on the biological behavior of breast carcinoma cells. METHODS: Erbin-ShRNA was transfected into MDA-MB-231 cells to construct an Erbin knockdown cell model. The change of cell morphology was observed under inverted microscope. The change of the expression of Erbin protein was subsequently detected by Western bloting. The change of the effect of cell migration was tested by Tr- answell chambers. The change of the effect of cell invasion was assessed by Matrigel-Transwell. The change of the expression of metastasis-related marker matrix metalloproteinase-2 (MMP-2) and metastasis-related marker matrix metallopro- teinase-9 (MMP-9) were detected by Western blotting. RESULTS.. Erbin-ShRNA resulted in remarkable suppression of Erbin expression in the breast carcinoma cells. Cells were longer and more shuttle, the gap was widened. Meanwhile, the invasion (56.3±7.6 vs 29.3±2.1,t=-5. 908,P=0. 004) and migration (83.6±7.2 vs 52.6±8.3,t=--4. 868,P= 0. 008) potential of MDA-MB-231 cells were enhanced after Erbin gene silencing,and the expression of metastasis-related marker matrix MMP-2 (0. 74 ± 0. 021 vs 0. 25 ± 0. 039, t = - 19. 23, P=0. 001), metastasis-related marker MMP-9 (0.78±0. 037 vs 0. 32±0. 078, t = -10.02, P = 0. 001) were significantly amplified. CONCLUSION.. Down-regulation of Erbin gene expression can promote malignant biological behavior of breast carcinoma cells, which can promote cells becoming longer and more shuttle,can enhance the invasion and migration potential of MDA-MB-231 cells.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2013年第17期1291-1294,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 国家自然科学基金(30871172 30971372)
关键词 ERBIN RNA干扰 乳腺肿瘤 侵袭 迁移 Erbin RNA interference breast neoplasms invasion migration
  • 相关文献

参考文献4

二级参考文献152

  • 1Hagedorn HG, Bachmeier BE, Nerlich AG. Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas. Int J Oncol 2001; 18:669-681. 被引量:1
  • 2Dickson MC, Martin JS, Cousins FM, Kulkami AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 1995; 121:1845-1854. 被引量:1
  • 3Larsson J, Goumans M J, Sjostrand L J, et al. Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type Ⅰ receptor-deficient mice. EMBO J 2001; 20:1663-1673. 被引量:1
  • 4Oshima M, Oshima H, Taketo MM. TGF-beta receptor type Ⅱ deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 1996; 179:297-302. 被引量:1
  • 5Steams ME, Garcia FU, Fudge K, Rhim J, Wang M. Role of interleukin 10 and transforming growth factor betal in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined irnmunodeficiency mice. Clin Cancer Res 1999: 5:711-720. 被引量:1
  • 6Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:442-454. 被引量:1
  • 7Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol 2007; 9:1000-1004. 被引量:1
  • 8Miettinen P J, Ebner R, Lopez AR, Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal ceils: involvement of type Ⅰ receptors. J Cell Biol 1994; 127:2021-2036. 被引量:1
  • 9Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-betal and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996; 10:2462-2477. 被引量:1
  • 10Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. Regulation of the polarity protein Par6 by TGF- beta receptors controls epithelial cell plasticity. Science 2005; 307:1603-1609. 被引量:1

共引文献92

同被引文献36

  • 1Kaur A,Dasanu C A. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma[J].{H}EXPERT OPINION ON PHARMACOTHERAPY,2011,(16):2493-2503. 被引量:1
  • 2Mukohara T. Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer[J].Chemother Res Pract,2011.730360. 被引量:1
  • 3Saxena R,Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer:current status and future clinical perspective[J].{H}Medicinal Research Reviews,2012,(01):166-215. 被引量:1
  • 4Mukai H. Treatment strategy for HER2-positive breast cancer[J].{H}International Journal of Clinical Oncology,2010,(04):335-340. 被引量:1
  • 5Slamon D J,Leyland Jones B,Shak S. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2[J].{H}New England Journal of Medicine,2001,(11):783-792. 被引量:1
  • 6Extra J M,Cognetti F,Chan S. 672 Randomised phase Ⅱ trial (M77001) of trastuzumab (Herceptin(R[J].{H}EUROPEAN JOURNAL OF CANCER,2003,(05):S202. 被引量:1
  • 7Von Minckwitz G,Zielinski C,Maarteense E. Capecitabine vs.capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment:The TBP phase Ⅲ study (GBG 26/BIG 3-05)[J].{H}Journal of Clinical Oncology,2008,(15):1025. 被引量:1
  • 8Kaufman B,Mackey J R,Clemens M R. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive,hormone receptor-positive metastatic breast cancer:results from the randomized phase Ⅲ TAnDEM study[J].{H}Journal of Clinical Oncology,2009,(33):5529-5537. 被引量:1
  • 9Jones K L,Buzdar A U. Evolving novel anti-HER2 strategies[J].{H}LANCET ONCOLOGY,2009,(12):1179-1187. 被引量:1
  • 10Baselga J,Gelmon K A,Verma S. Phase Ⅱ trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy[J].{H}Journal of Clinical Oncology,2010,(07):1138-1144. 被引量:1

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部